MSKCC Chief Medical Residents

Chief Residents of the transitional year and internal medicine rotator program at MSKCC.

[MSK Department of Medicine @MSK_DeptOfMed]

Happy holidays to our colleagues in the Department of Medicine and throughout @MSKCancerCenter. Thank you for everything you do for your patients, coworkers, and our community every day. We're so grateful for you and wish you fulfillment, peace, health, and joy in 2023.

[Journal of Brown Hospital Medicine @BrownJHM]

What the inside of an artery actually looks like via Dr. Stephen Bonsib #Medtwitter

[Eileen M O’Reilly @EileenMOReilly]

Please join us 11/18/2022 MSK Pancreas Cancer Symposium! All star @DrVickersMSK @GMPetersen1 @SharifEllozy #RohitChandawani @CFerroneMD @MichaelDAngeli2 @wei_ac @W_Park_MD @MSKCancerCenter @CpcrMsk @DrRichardDo @TheVinodLab @MFBerger1 @drpeterkingham

[MSK Department of Medicine @MSK_DeptOfMed]

Excellent teaching case from Dr. James Harding’s clinic presented at resident report @MSK_MedChiefs and converted to a @JAMAOnc Clinical Challenge with @BinbinZhengLin and @DavidFaleckMD.

Great medical educational opportunities at @MSKCancerCenter!

📖: https://t.co/3YaENcb1Us

[Krunal H. Patel ⚕️ @MDKrunalP]

On the weekend book club list. Must read for anyone interested in a more patient centered delivery of healthcare, post ICU syndrome (PICS), or anyone interested in critical care. Great read by @WesElyMD 🫁 🙏🏽

[MSKCC Chief Medical Residents @MSK_MedChiefs]

Congrats to everyone who matched yesterday! For anyone out there applying for TY programs currently—we have the BEST TY class in the country 💯! You guys have large shoes to fill :-)

[MSKCC Chief Medical Residents @MSK_MedChiefs]

Excited to share this article written by our TY @alexgoglia on randoc alternative payment models👏🏻👏🏻👏🏻

[Alex Goglia @alexgoglia]

Online just in time for the end of ASTRO! I was fortunate to work with @PPendyalaMD @RonEnnisMD1 and @DrJohnSuh to write this article exploring how the new radonc alternative payment model (RO-APM) will impact large academic centers. https://t.co/6cqGrxvq7G

[MSKCC Chief Medical Residents @MSK_MedChiefs]

Proud to share this insightful article written by our TY @EChrisDee 👏👏

[Edward Christopher "Chris" Dee, MD @EChrisDee]

Proud to share my Perspective in @TheLancetOncol, an exploration of the #lessons we are privileged to learn from our #patients with #cancer.

They are our greatest #teachers.

@MSK_RadOnc @sloan_kettering @DanaFarber @harvardmed #Oncology #medtwitter

https://t.co/m04p8Ov0zH

[MSKCC Chief Medical Residents @MSK_MedChiefs]

We are so excited about this incredible opportunity to learn about pancreas cancer from the best! Last chance to register😁

[Eileen M O’Reilly @EileenMOReilly]

We look forward to our MSK Pancreas CME Symposium on Wed 11-03-2021. Terrific faculty and broad topics. Please join us!
https://t.co/GtWr1QeWgh

[MSKCC Chief Medical Residents @MSK_MedChiefs]

So proud to see the outstanding research work of our TYs!

@EChrisDee @KaitlynLapen

[Edward Christopher "Chris" Dee, MD @EChrisDee]

Smiling like mad under the #masks —

SO honored to be at my first in-person #ASTRO #ASTRO2021 with ⁦@KaitlynLapen⁩ and ⁦@chr_huang⁩ and grateful to be in #radonc with the gang! 😁

[Yelena Y. Janjigian MD @YJanjigianMD]

I got to spend the week with this excellent team of residents rounding @sloan_kettering. Up next they get to round with DOM Chair. Thank you for covering the service this weekend Deb Schrag @debschrag. @MSK_MedChiefs @MSKEducation

[MSKCC Chief Medical Residents @MSK_MedChiefs]

For more information, please check out this amazing review on JAMA, written by @W_Park_MD, @MDAkhilChawla, and @EileenMOReilly
https://t.co/5aYueW1g3m

[MSKCC Chief Medical Residents @MSK_MedChiefs]

Today we had a fantastic academic time lecture with Dr. @EileenMOReilly on pancreatic ductal adenocarcinoma (PDAC), please see #tweetorial below:
#MedEd #PancreaticCancer #PDAC

[MSKCC Chief Medical Residents @MSK_MedChiefs]

The mainstay of treatment for stage IV disease is cytotoxic chemotherapy; a subset of pts may benefit from immunotherapy (if dMMR/MSI-H), PARPi (gBRCA1/2-mutated), and NTRK inhibition

[MSKCC Chief Medical Residents @MSK_MedChiefs]

Maintenance olaparib is recommended for pts with platinum-sensitive gBRCA1/2-mutated PDAC. Common side effects are myelosuppression and GI toxicity; MDS and AML may occur in rare cases

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

“When we talk about cancer #healthequity, we want every patient who has #cancer to have the best possible outcome," says @drcarolbrownMSK, who recently participated in @BeckersHR Fireside Chat on Health Equity. See more of her insights below. https://t.co/jq9habMgue